PCV13

PCV13

An abbreviation for a pneumococcal polyvalent vaccine composed of 13 capsular antigens of Streptococcus pneumoniae. It is used, like PCV7, to immunize children against pneumococcal diseases, e.g., otitis media, pneumonia, meningitis.
References in periodicals archive ?
ACIP also recommended that the 13-valent pneumococcal conjugate vaccine (PCV13) be given "based on shared clinical decision making" in adults 65 and older who do not have a weakened immune system and who have not previously received PCV13.
The dose of PPSV23 should be given 12 months after a dose of PCV13.
Pneumococcal vaccination with the 13-valent pneumococcal conjugate vaccine (PCV13) based on shared clinical decision making is recommended for immunocompetent adults aged 65 years and older who have not previously received PCV13, and all adults aged 65 years and older should continue to receive the pneumococcal polysaccharide vaccine (PPSV23), according to a vote at a meeting of the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices.
Paul Hunter, MD, of the City of Milwaukee Health Department, voted against the shared clinical decision making, and instead favored discontinuing the recommendation for PCV13 for older adults.
National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey for three time periods: pre-PCV7 (1997-1999), after the introduction of PCV7 (2001-2009), and after the introduction of PCV13 (2011-2013).
V114 also induced an immune response in infants for two additional disease-causing serotypes, 22F and 33F, which are not contained in PCV13. In January 2019, V114 received a Breakthrough Therapy Designation from the U.S.
There are two pneumonia vaccines: Pneumococcal Conjugate Vaccine, and PCV13 (Prevnar), and Pneumococcal Polysaccharide Vaccine, or PPSV23 (Pneumovax).
The pneumonia vaccine PCV13 provides protection against a fairly wide variety of pneumonia organisms.
Vaccination coverage remains low: nationwide administrative coverage for the first dose of 13-valent pneumococcal conjugate vaccine (PCV13) was 77% in 2016 and 52% for the third dose.
Initially PCV13 was reserved for young children; however, in 2012 it was licensed for use in adults because of its immunogenicity (Tomcyzk et al., 2014).
Patients with pneumonias caused by pneumococcal serotypes included in PCV13 were considered "cases," and "control" subjects were patients with CAP who tested negative for PCV13 serotypes.